A leading market player in Life Sciences and Clinical Diagnostics, faced significant challenges in China, despite it being one of their fastest-growing markets. A strategic cross-functional assessment based on an in-depth due diligence covering all major value streams revealed issues including declining growth, misaligned portfolios and an underperforming marketing & sales organization. This was addressed in a comprehensive growth initiative, which included restructuring of management and governance processes, efforts to redirect the product development portfolio and enhancing sales channels. A bold plan, underpinned by a substantial double-digit million USD investment, established a significant turnaround, with substantial revenue growth. By addressing internal challenges and seizing market opportunities, the company was set to transform its China business, reaffirming its commitment to growth and innovation in a vital global market.